Menu Search
Equities

Zealand Pharma A/S

22Z:STU

Zealand Pharma A/S

Actions
  • Price (EUR)118.60
  • Today's Change-3.30 / -2.71%
  • Shares traded0.00
  • 1 Year change+199.04%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Zealand Pharma A/S grew revenues 229.65% from 103.99m to 342.79m while net income improved from a loss of 1.20bn to a smaller loss of 703.74m.
Gross margin90.96%
Net profit margin-193.49%
Operating margin-198.85%
Return on assets-11.67%
Return on equity-12.80%
Return on investment-12.12%
More ▼

Cash flow in DKKView more

In 2023, cash reserves at Zealand Pharma A/S fell by 619.92m. Cash Flow from Financing totalled 907.01m or 264.60% of revenues. In addition the company used 425.67m for operations while cash used for investing totalled 1.09bn.
Cash flow per share--
Price/Cash flow per share--
Book value per share132.48
Tangible book value per share132.31
More ▼

Balance sheet in DKKView more

Zealand Pharma A/S has little financial risk as the capital structure does not rely on leverage.
Current ratio35.57
Quick ratio35.57
Total debt/total equity0.0415
Total debt/total capital0.0399
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.